
Amniotic Products Market Report 2026
Global Outlook – By Type (Amniotic Membranes, Amniotic Suspensions), By Application (Wound Care, Orthopedics, Ophthalmology, Other Applications), By End-Use (Hospitals And Ambulatory Surgical Centers, Other End Users) - Market Size, Trends, And Global Forecast 2026-2035
Amniotic Products Market Overview
• Amniotic Products market size has reached to $1.08 billion in 2025 • Expected to grow to $1.65 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Amniotic Products Market Growth Fueled By Increasing Demand In Surgical Procedures • Market Trend: Innovations In Dual Layer Amniotic Allografts Enhance Wound Healing And Surgical Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Amniotic Products Market?
Amniotic products refer to ortho-biologic products and involve using amniotic-derived products, such as amniotic membrane and fluid products, to enhance joint inflammation and healing. Administration of amniotic products at the injury site helps recovery by stimulating tissue growth. The main types of amniotic products are amniotic membranes and amniotic suspensions. Amniotic membranes refer to the placenta's innermost layer and are made up of a thick foundation membrane and an avascular stromal matrix that is used for a surgical dressing for burns, adjunctive tissue in the restoration of the oral cavity and bladder, as well as tympanoplasty, arthroplasty, omphalocele repair, and adhesion prevention in pelvic and abdominal surgery. They are used for wound care, orthopedics, ophthalmology, and others by hospitals and ambulatory surgical centers, and others.
What Is The Amniotic Products Market Size and Share 2026?
The amniotic products market size has grown strongly in recent years. It will grow from $1.08 billion in 2025 to $1.17 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to growth of orthobiologic treatment adoption, increasing sports injury incidence, expansion of minimally invasive treatment options, availability of amniotic-derived formulations, acceptance of biologic healing solutions.What Is The Amniotic Products Market Growth Forecast?
The amniotic products market size is expected to see strong growth in the next few years. It will grow to $1.65 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing demand for regenerative orthopedic therapies, rising focus on pain management alternatives, expansion of outpatient musculoskeletal treatments, growing investments in biologic product development, increasing clinical evidence supporting amniotic products. Major trends in the forecast period include increasing adoption of amniotic-based orthobiologics, rising use in sports medicine applications, expansion of injectable amniotic suspensions, growing focus on non-surgical healing therapies, enhanced integration with regenerative treatment protocols.Global Amniotic Products Market Segmentation
1) By Type: Amniotic Membranes, Amniotic Suspensions 2) By Application: Wound Care, Orthopedics, Ophthalmology, Other Applications 3) By End-Use: Hospitals And Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Amniotic Membranes: Dehydrated Amniotic Membranes, Cryopreserved Amniotic Membranes 2) By Amniotic Suspensions: Liquid Amniotic Suspensions, Lyophilized Amniotic SuspensionsWhat Is The Driver Of The Amniotic Products Market?
The increasing demand in surgical procedures is expected to propel the growth of the amniotic products market going forward. Surgical procedures refer to medical interventions performed by a qualified surgeon to treat, repair, remove, or replace a part of the body that may be affected by disease, or injury. Amniotic products are beneficial in surgical procedures as they promote tissue regeneration and healing, reduce inflammation at the surgical site, contribute to faster recovery and reduced postoperative discomfort, reduce pain, and enhance tissue repair and protection. For instance, in June 2024, according to the data published by the American Society of Plastic Surgeons (ASPS), a US-based plastic surgery specialty organization, liposuction was the most popular plastic surgery in 2023, with nearly 350,000 procedures performed, a 7% increase from 2022, while hand surgeries totaled 207,887, up 2%, and maxillofacial surgeries reached 52,868, a 1% rise compared to the previous year. Therefore, the increasing demand in surgical procedures is driving the growth of the amniotic products industry.Key Players In The Global Amniotic Products Market
Major companies operating in the amniotic products market are Stryker Corporation, Smith & Nephew plc, Integra LifeSciences Holdings Corporation, Lucina BioSciences LLC, Bioventus LLC, Organogenesis Inc., MiMedx Group, AlloSource, Orthofix US LLC, ACell Inc., Aziyo Biologics Inc., TissueTech Inc., Amino Technology LLC, LifeCell International Pvt. Ltd., Tissue Regenix Group plc, Aroa Biosurgery Limited, Skye Biologics Inc., Celularity Inc., NuVision Biotherapies Ltd., VIVEX Biologics Inc., Genesis Biologics Inc., Applied Biologics LLC, Next Biosciences, Surgenex LLCGlobal Amniotic Products Market Trends and Insights
Major companies operating in the amniotic products market are focusing on developing next-generation dual-layer allografts to strengthen their product portfolios and address complex wound care needs. Dual-layer allografts comprise two layers of amniotic tissue, providing enhanced structural integrity, improved growth-factor retention, and longer resorption times, making them suitable for surgical wounds, burns, and chronic non-healing wounds. For instance, in June 2024, Ascension Biologics, a U.S.-based tissue company, launched AMNIO MAXX®, a dual-layer amnion allograft that delivers twice the growth factors compared to traditional single-layer membranes, improved tensile strength, and flexible placement due to its orientation-independent design. Designed to support tissue regeneration and optimize wound healing in complex surgical applications, AMNIO MAXX exemplifies the technological advancements transforming the competitive landscape of the amniotic products market.What Are Latest Mergers And Acquisitions In The Amniotic Products Market?
In August 2025, Legacy Medical Consultants, a U.S.-based provider of amniotic allografts and advanced wound-care solutions, acquired the U.S. rights to sell RedDress’s ActiGraft Pro for an undisclosed amount. With this acquisition, the company aims to expand its wound-care portfolio beyond amniotic products by adding a personalized, autologous treatment that strengthens its capabilities across hospitals, outpatient centers, and government care settings. RedDress is an Israel-based provider of autologous whole-blood clot wound-care technologies designed to support the healing of chronic, non-healing wounds.Regional Outlook
North America was the largest region in the amniotic products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Amniotic Products Market?
The amniotic products market consists of sales of amniotic tissue matrix and amniotic fluid cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Amniotic Products Market Report 2026?
The amniotic products market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the amniotic products industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Amniotic Products Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $1.17 billion |
| Revenue Forecast In 2035 | $1.65 billion |
| Growth Rate | CAGR of 8.7% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Type, Application, End-Use |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Stryker Corporation, Smith & Nephew plc, Integra LifeSciences Holdings Corporation, Lucina BioSciences LLC, Bioventus LLC, Organogenesis Inc., MiMedx Group, AlloSource, Orthofix US LLC, ACell Inc., Aziyo Biologics Inc., TissueTech Inc., Amino Technology LLC, LifeCell International Pvt. Ltd., Tissue Regenix Group plc, Aroa Biosurgery Limited, Skye Biologics Inc., Celularity Inc., NuVision Biotherapies Ltd., VIVEX Biologics Inc., Genesis Biologics Inc., Applied Biologics LLC, Next Biosciences, Surgenex LLC |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
